Xolair is an unusually hard drug to price because two patients on the same medicine can be billed eight times differently. The dose is set by body weight and by a blood IgE level drawn before treatment starts, so it ranges from 75 mg to 600 mg, given every two or four weeks. That is a sixteen-fold spread in drug cost before anyone talks about where the shot is given.
This guide prices the drug per dose using the two figures that are actually published, Medicare’s Part B payment limit and the cash pharmacy price, then walks through the dosing math, the administration fee, the two Genentech assistance programs and their very different eligibility rules, and where the first omalizumab biosimilar stands as of September 2026.
What Does Xolair Cost Without Insurance?
Xolair bills two ways depending on where you get it. Under the medical benefit it is HCPCS J2357, “injection, omalizumab, 5 mg,” bought and billed by the clinic. Under the pharmacy benefit it is a prefilled syringe or autoinjector dispensed to you.
For the July 1 through September 30, 2026 quarter, CMS set the Part B payment limit for J2357 at $46.588 per 5 mg unit, based on first-quarter 2026 average sales price data. A 150 mg dose is 30 units, so $1,397.64. A 300 mg dose is 60 units, so $2,795.28.
On the pharmacy side, Drugs.com’s cash price guide lists the 150 mg/mL solution at $1,164.54 to $1,467.86 per milliliter and the 75 mg/0.5 mL presentation from $587.02, as of September 2026.
| Xolair dose or item | Low | Average | High |
|---|---|---|---|
| 75 mg dose, drug only | $587 | $699 | $1,287 |
| 150 mg dose, drug only | $1,165 | $1,398 | $2,573 |
| 300 mg dose, drug only | $2,329 | $2,795 | $5,147 |
| Injection administration (CPT 96372) | $13 | $15 | $55 |
| One month at 150 mg every 4 weeks | $1,180 | $1,413 | $2,629 |
| One month at 300 mg every 2 weeks | $4,689 | $5,621 | $10,404 |
The “low” column is the Drugs.com cash pharmacy price. The “average” column is Medicare’s Part B payment limit for the current quarter. The “high” column is the average charge providers actually submitted to Medicare for J2357 in the 2024 data year, $85.775 per 5 mg unit, which works out to $2,573.26 for 150 mg. Medicare allowed an average of $36.955 per unit against that submitted charge, which tells you how far a chargemaster price can sit above what anyone actually pays.
Genentech itself only publishes an annual figure. Xolair.com states the current list price, defined as wholesale acquisition cost, is approximately $30,000 to $60,000 annually. Genentech does not publish a per-vial or per-syringe WAC, so the per-dose figures above come from CMS and from the pharmacy cash market rather than from the manufacturer.
What Drives the Price
Your weight and your IgE level
This is the dominant factor. Genentech’s prescribing information, revised August 2026, sets asthma dosing at 75 to 375 mg every two or four weeks, chronic rhinosinusitis with nasal polyps at 75 to 600 mg, and IgE-mediated food allergy at 75 to 600 mg, all determined by serum total IgE measured before treatment plus body weight. Only chronic spontaneous urticaria is dose-flat, at 150 or 300 mg every four weeks regardless of weight or IgE.
That means a small adult with modest IgE on 150 mg every four weeks is looking at roughly $15,000 a year in drug cost, while a heavier patient on 375 mg every two weeks is over $80,000. Both are “on Xolair.”
Whether you are on the medical benefit or the pharmacy benefit
The Part B route means the clinic buys the drug and bills J2357 plus an administration code. The pharmacy route means you or a specialty pharmacy pay for the syringe and it is self-injected after training. The pharmacy cash price we found is roughly 17 percent below the Part B payment limit for 150 mg, so for a cash payer the pharmacy channel is usually the cheaper of the two on the drug itself.
The administration fee, and which code gets used
A subcutaneous injection in an office is CPT 96372, which carries 0.46 total RVUs. At the 2026 conversion factors of $33.4009 and $33.5675 that is $15.36 to $15.44 nationally. National Medicare claims data shows an average submitted charge of $55.33 for 96372 in the office setting against $13.42 allowed.
You may occasionally see CPT 96401, chemotherapy administration by subcutaneous or intramuscular route for a non-hormonal anti-neoplastic. It carries 2.15 RVUs, or about $72, roughly five times 96372. Xolair is not an anti-neoplastic, so 96401 is the wrong code for it. If it shows up on your bill, question it.
Site of care
A hospital outpatient department adds a facility charge on top of both the drug and the administration. That charge does not appear in any of the numbers above and can easily exceed the injection fee itself. Getting the same injection in an independent allergy or pulmonology office removes it. Pull the hospital’s posted rate first using our price transparency guide.
Quarterly repricing
Part B payment limits are recalculated every quarter from manufacturer-reported average sales price data. The $46.588 figure above is specific to the July through September 2026 quarter. The next reset is October 1, 2026, and the number will move.
Cash Price vs. Insurance
For Xolair the honest answer is that paying cash is almost never the right plan, and the cheapest path for an uninsured patient is not a discount at all. It is free drug.
The Genentech Patient Foundation supplies Genentech medicines at no cost to patients with no insurance coverage for the drug whose household income is under $150,000 a year, adding $25,000 for each additional person in households larger than four. That threshold is unusually generous for a manufacturer program, and it is stated on Genentech’s own FAQ page. Genentech lists (888) 941-3331 for Foundation specialists. Insured patients with unaffordable out-of-pocket costs can also apply, but are asked to try other assistance first.
The Xolair Co-pay Program is the opposite: it is generous but only for commercially insured patients. The drug program covers up to $15,000 per calendar year and the separate administration program covers up to $1,500, with no income limits. Genentech’s terms require commercial private or non-governmental insurance, including marketplace plans, and explicitly exclude anyone with Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD or TRICARE coverage. If you are uninsured, this card does nothing for you.
One quirk worth knowing: Genentech’s own terms say patients receiving free drug from the Patient Foundation may still use the Co-pay Program for their injection costs. The administration program is also void for Massachusetts and Rhode Island residents.
Where the biosimilar stands
Omlyclo (omalizumab-igec), from Celltrion, appears on FDA’s biosimilar product list with a March 2025 approval date and is the only omalizumab biosimilar on that list, which was current as of August 4, 2026. It carries an interchangeability designation, meaning a pharmacist may substitute it for Xolair subject to state law.
What has not happened yet is a published price to compare against. The July 2026 Medicare Part B payment limit file lists a rate for J2357 and no separate payment limit for an omalizumab biosimilar HCPCS code. Until a biosimilar rate appears in a quarterly ASP file or a cash price is posted, there is no verified discount to quote. Ask your prescriber and your pharmacy whether Omlyclo is stocked and what it costs before assuming a biosimilar saves you money.
How to Pay Less
Apply to the Genentech Patient Foundation first, before anything else. At a $150,000 household income ceiling for patients with no coverage for the drug, this is the single largest lever available and it makes every other tactic on this list secondary. Start at the Foundation FAQ or call the number Genentech publishes.
Price the pharmacy channel against the buy-and-bill channel. The prefilled syringe and autoinjector are self-administered after training, per the prescribing information. For a cash payer that removes both the clinic’s drug markup and the administration and facility fees.
Refuse to accept a hospital outpatient facility fee without seeing it. Ask for an itemized bill and check whether a facility line sits alongside J2357 and 96372. If it does, the same injection in an office setting eliminates it.
Negotiate any balance that lands anyway. Specialty drug bills are one of the most negotiable categories in healthcare because the billed charge sits so far above the allowed amount. The 2024 claims data above shows J2357 billed at $85.78 per unit against $36.96 allowed. Our negotiation guide covers the approach, and hospital-affiliated infusion clinics fall under the parent system’s charity care policy.
Ask whether a cheaper biologic or a non-biologic path fits your condition. Cost is not a clinical argument, but it is worth knowing the landscape before you commit. Compare Nucala, Tezspire and Dupixent for asthma, and for allergic rhinitis specifically, allergy shots and Flonase sit at a completely different price point.
The Bottom Line
Xolair runs $1,165 to $1,398 per 150 mg dose as of September 2026, or $2,329 to $2,795 at 300 mg, with about $15 in Medicare-rate administration on top. Whether that becomes $15,000 or $80,000 a year depends on a dose your weight and IgE level determine, not on shopping.
For an uninsured patient, the practical answer is not a cash discount. It is the Genentech Patient Foundation’s $150,000 household income threshold. If you are being treated for food allergy, keep pricing rescue medication separately as well, including EpiPen and Neffy, since a biologic does not replace an epinephrine plan.